临床试验/NCT01875770

NCT01875770终止不适用

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Johns Hopkins University1 个研究点分布在 1 个国家目标入组 47 人开始时间: 2013年1月最近更新: 2021年10月12日

适应症

试验速览

阶段: 不适用
状态: 终止
发起方: Johns Hopkins University
入组人数: 47
试验地点: 1
主要终点: Mean change from baseline in BCVA at 5 and 10 years.

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

详细描述

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 99 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•All patients who have been enrolled in the following three trials will be included in the study:
•A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"

排除标准

未提供

结局指标

主要结局

Mean change from baseline in BCVA at 5 and 10 years.

时间窗: 10 years

Mean change from baseline in BCVA at 5 and 10 years.

次要结局

Mean change from baseline in foveal thickness at 5 and 10 years(10 years)

研究者

发起方

Johns Hopkins University

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Canadian Treat and Extend Analysis Trial With RanibizumabwetAMD

NCT02103738Novartis Pharmaceuticals505

已完成

4 期

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected EyeWet Age Related Macular Degeneration

NCT01986907Novartis Pharmaceuticals1,049

已完成

1 期

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular EdemaClinically Significant Diabetic Macular Edema

NCT00440609Philip J. ferrone, M.D.50

招募中

不适用

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum DisorderNeuromyelitis Optica

NCT06398158University of Texas Southwestern Medical Center35

已完成

2 期

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.Radiation Retinopathy

NCT02222610Greater Houston Retina Research40